Literature DB >> 28173994

Intraoperative high-dose-rate brachytherapy: An American Brachytherapy Society consensus report.

S Lloyd1, K M Alektiar2, S Nag3, Y J Huang1, C L Deufel4, F Mourtada5, D K Gaffney6.   

Abstract

PURPOSE: This report presents recommendations from the American Brachytherapy Society for the use of intraoperative high-dose-rate (IOHDR) brachytherapy. METHODS AND MATERIALS: Members of the American Brachytherapy Society with expertise in IOHDR formulated this document based on their clinical experience and a review of the literature. This report covers the use of IOHDR in colorectal cancer, soft tissue sarcoma, gynecologic cancers, head and neck cancers, and pediatric cancers. This report does not cover intraoperative brachytherapy for breast cancer. Details about treatment planning and delivery are emphasized so this document can serve as a guide to practices implementing this technique.
RESULTS: IOHDR brachytherapy is generally most beneficial for patients with either close or positive margins and/or recurrent disease in a previous resection bed or previously irradiated area. IOHDR brachytherapy requires a well-coordinated multidisciplinary team. IOHDR brachytherapy is recommended in the treatment of both recurrent and primary locally advanced disease for colorectal and gynecologic malignancies, soft tissue sarcoma, and selected head and neck and pediatric malignancies. Other techniques such as perioperative fractionated brachytherapy are also acceptable in many cases with some advantages and disadvantages compared to IOHDR.
CONCLUSIONS: IOHDR brachytherapy is a specialized technique in radiation therapy with unique properties and advantages in cancer control. Special considerations for treatment planning and delivery are outlined herein.
Copyright © 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Gynecologic cancer; Head and neck cancer; Intraoperative high-dose-rate brachytherapy; Pediatric cancer; Radiation planning; Sarcoma

Mesh:

Year:  2017        PMID: 28173994     DOI: 10.1016/j.brachy.2017.01.001

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  2 in total

1.  Experimental study of pelvic perioperative brachytherapy with iodine 125 seeds (I-125) in an animal model.

Authors:  Thomas Brun; Gwenael Ferron; Thomas Filleron; Jacques Bonnet; Alejandra Martinez; Anne Ducassou; Fabien Corbiere; Martine Delannes
Journal:  J Contemp Brachytherapy       Date:  2018-10-31

2.  Narrowing the difference in dose delivery for IOERT and IOBT for locally advanced and locally recurrent rectal cancer.

Authors:  An-Sofie E Verrijssen; Wim J F Dries; Jeltsje S Cnossen; Jacqueline Theuws; Heike M U Peulen; Hetty A van den Berg; Dorien C Rijkaart; Eva L K Voogt; Inger-Karine Kolkman-Deurloo; Joost Nuyttens; Harm J T Rutten; Jacobus W A Burger; Cathryn Huibregtse Bimmel-Nagel
Journal:  J Contemp Brachytherapy       Date:  2022-07-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.